The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.

Moderna’s stock (NASDAQ: MRNA) has plummeted over 80% in the past year, largely due to challenges in its vaccine sales. Last year, the company announced lower sales projections in Europe ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s skepticism of mRNA vaccines has cost the company dearly.

The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it worse.

The Food and Drug Administration has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike.

Moderna Inc. has agreed to do a placebo-controlled trial of its new Covid vaccine that was recently approved by US regulators, Health and Human Services Secretary Robert F. Kennedy Jr. said Tuesday.

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules.

Moderna's (MRNA) new COVID vaccine approval targets a broader high-risk population. Check out why I see potential for a 25-40% share price gain in 2025.